EASD 2026: Petrelintide pairs 10.7% weight loss with placebo-like GI tolerability
ZUPREME-1 positions petrelintide as a tolerability-led rather than efficacy-led entrant.
ZUPREME-1 positions petrelintide as a tolerability-led rather than efficacy-led entrant.